Conference Coverage

Featured Image - San Diego, CA at night. Courtesy 2019 Fotolia

Zymeworks Wins Best ADC Platform Technology Award for ZymeLink

Zymeworks, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics including bispecific antibodies and bispecific antibody-drug conjugates across a wide range...
Downtown San Diego, CA. Courtesy: 2019 David Cruz/Sunvalley Communication

Abzena to Offer New, Integrated, Clinical Translation Service

Abzena, a life sciences company providing a series of specific serviced for the development of antibody-drug conjugates, earlier this...
The AACR 2019 Annual Meeting - Poster Session during the American Association for Cancer Research (AACR) Annual Meeting, Sunday March 31, 2019. Courtesy: © AACR/Todd Buchanan 2019

Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at Bolt Biotherapeutics

Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the...

Sutro Biopharma to Receive Milestone Payment from Merck KGaA for Bispecific ADC Candidate

Sutro Biopharma has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA,...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development

Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development...

Comprehensive Service Accelerates Development of ADCs and Reduces Time to Clinic

A new service called ADC Express™services, launched by MilliporeSigma, allows for the rapid production of Antibody-drug Conjugates or ADCs....

World ADC 2019: Maximizing the Clinical Therapeutic Index of Antibody-drug Conjugates

With five approved and commercially available antibody-drug conjugates and nearly 100 in various stages of clinical development, it is...

ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression

The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

FORWARD II Triplet Combination Demonstrates Encouraging Anti-tumor Activity

Safety and overall response data from the Phase Ib FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Sacituzumab Govitecan Achieves 29 Percent ORR in Advanced Urothelial Cancer

Interim data from a 100-patient cohort of cisplatin-eligible patients participating in the TROPHY-U-01, an international, multi-center, open-label, phase II...